The global renal biomarker market is on a robust growth trajectory, projected to surge from USD 1,541.2 million in 2024 to an impressive USD 3,031.8 million by 2034. This growth represents a compound ...

The global teleradiology services market is poised for exceptional growth over the next decade. Valued at approximately USD 8,894.3 million in 2024, the market is projected to reach USD 9,731.4 ...

The global central venous catheter market is on a strong upward trajectory, with projections indicating a rise from USD 2,861.0 million in 2024 to a remarkable USD 5,436.8 million by 2034. This growth ...

The global medical cleaning devices market is poised for transformative growth, with projections estimating its valuation to surge from USD 28,462.09 million in 2025 to an impressive USD 75,861.59 ...

The global dissolving microneedle market value is expected to rise from USD 47.2 million in 2024 to USD 118.5 million by 2034. This estimated growth is expected to be driven by a promising CAGR of ...

The global ligament augmentation market is on a significant growth trajectory, projected to grow from USD 51.15 million in 2025 to approximately USD 84.12 million by 2035, reflecting a CAGR of 5.1% ...

Sartorius Stedim Biotech SA / Key word (s): Quarter Results/Forecast Sartorius Stedim Biotech publishes unaudited first quarter results for 2025 16-Apr-2025 / 07:00 CET/CEST Sales revenue at 745 ...

MURFREESBORO, TN / ACCESS Newswire / April 15, 2025 / National Health Investors, Inc. (NYSE:NHI) announced details for the release of its results for the first quarter ended March 31, 2025. NHI plans ...

VANCOUVER, BC / ACCESS Newswire / April 15, 2025 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is pleased to announce that Company completed its previously ...

GOTHENBURG, SE / ACCESS Newswire / April 15, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report January-March 2025.

Sanofi today shared new progress from its mid- to late-stage respiratory pipeline, including preliminary phase 2 results for amlitelimab in adults with moderate-to-severe asthma.

CHEYENNE, WY / ACCESS Newswire / April 15, 2025 / Neuss, Germany: CS Diagnostics Corp. is pleased to announce that it has received a Letter of Intent from SAN ART CAPITAL SAS, a leading advisory and ...